(Q37670068)

21 August 2017

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms (English)

1 reference

21 August 2017

13

Gabriela Chiosis

0 references

author name string

Neha Bhagwat

1

1 reference

21 August 2017

Priya Koppikar

2

1 reference

21 August 2017

Matthew Keller

3

1 reference

21 August 2017

Sachie Marubayashi

4

1 reference

21 August 2017

Kaitlyn Shank

5

1 reference

21 August 2017

Raajit Rampal

6

1 reference

21 August 2017

Jun Qi

7

1 reference

21 August 2017

Maria Kleppe

8

1 reference

21 August 2017

Hardik J Patel

9

1 reference

21 August 2017

Smit K Shah

10

1 reference

21 August 2017

Tony Taldone

11

1 reference

21 August 2017

James E Bradner

12

1 reference

21 August 2017

Ross L Levine

14

1 reference

21 August 2017

language of work or name

English

0 references

publication date

27 January 2014

1 reference

21 August 2017

1 reference

21 August 2017

123

1 reference

21 August 2017

13

1 reference

21 August 2017

2075-2083

1 reference

Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor

21 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

A gain-of-function mutation of JAK2 in myeloproliferative disorders

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Jak2 is essential for signaling through a variety of cytokine receptors

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968390

10.1182/BLOOD-2014-01-547760

25 June 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

21 August 2017

PubMed publication ID

24470592

1 reference